Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.18 +0.08 (+0.33%)

Streaming Delayed Price Updated: 11:50 AM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗

January 22, 2026

Via Chartmill

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

How Is The Market Feeling About Pfizer Inc? ↗

January 22, 2026

Via Benzinga

Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap? ↗

January 22, 2026

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Via The Motley Fool

Topics Intellectual Property

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗

January 21, 2026

Via Stocktwits

Cayenne Wellness Center Celebrates 25 Years of Impact With Star-Studded Fundraising Gala

January 22, 2026

January 22, 2026 -- Supporting Sickle Cell Wellness

Via 24-7 Press Release

Is This Dividend King Stock a Buy After a Major Development? ↗

January 21, 2026

After a strong performance in 2025, Johnson & Johnson is starting the new year right.

Via The Motley Fool

Topics Government World Trade

Why Are Novavax (NVAX) Shares Soaring Today

January 21, 2026

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant...

Via StockStory

Topics Artificial Intelligence Supply Chain

Beyond the Silicon: NVIDIA and Eli Lilly Launch $1 Billion ‘Physical AI’ Lab to Rewrite the Rules of Medicine

January 21, 2026

In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the...

Via TokenRing AI

Topics Artificial Intelligence Economy Intellectual Property

J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape

January 21, 2026

NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,...

Via MarketMinute

Topics Earnings Economy Government

3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer ↗

January 21, 2026

One of these suggested stocks features a dividend yield topping 10%.

Via The Motley Fool

Topics Intellectual Property

Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment

January 20, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

The 50.9 Mirage: Is the Manufacturing Expansion a True Recovery or a Tariff-Induced Sugar High?

January 20, 2026

The American manufacturing sector has finally crossed the threshold into expansion territory, with the latest Institute for Supply Management (ISM) Manufacturing PMI rising to 50.9. This mark...

Via MarketMinute

Topics Economy Supply Chain World Trade

These S&P500 stocks are the most active in today's session ↗

January 20, 2026

Via Chartmill

Novavax Shares Rise After Licensing Deal With Pfizer ↗

January 20, 2026

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for Matrix-M adjuvant.

Via Benzinga

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗

January 20, 2026

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

Via Stocktwits

Down 55%, Should You Buy the Dip on Pfizer? ↗

January 19, 2026

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Via The Motley Fool

Topics Intellectual Property

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine

January 19, 2026

In a move that signals a paradigm shift for the pharmaceutical industry, NVIDIA (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) have announced the launch of a $1 billion joint AI co-innovation...

Via TokenRing AI

Topics Artificial Intelligence

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

Via Finterra

Topics Economy

1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm

January 18, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Topics Intellectual Property

2 of Wall Street’s Favorite Stocks with Solid Fundamentals and 1 Facing Challenges

January 18, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026 ↗

January 18, 2026

Making passive income isn't easy, but it's achievable with these stocks.

Via The Motley Fool

Topics Artificial Intelligence Earnings Energy

The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS) ↗

January 17, 2026

All three of these stocks sport dividend yields above 6%.

Via The Motley Fool

Topics Intellectual Property

Top Picks 2026: Pfizer Inc. ↗

January 17, 2026

As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc., which has climbed its own crowded wall of...

Via Talk Markets

Wall Street’s Comeback King: Citigroup Shatters M&A Records as Jane Fraser Sets a High Bar for 2026

January 16, 2026

Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal...

Via MarketMinute

Topics Artificial Intelligence Economy

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Topics Initial Public Offering Intellectual Property Lawsuit

NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? ↗

January 16, 2026

The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.

Via Stocktwits

3 Cash-Producing Stocks with Questionable Fundamentals

January 15, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.